Stem Cells, Cell Therapies, and Bioengineering in Lung Biology and Lung Diseases

利用干细胞或生物工程组织修复和再生病变肺是令人兴奋的潜力 各种肺部疾病和危重疾病的治疗方法。越来越多的临床前证据 模型表明，非正常驻留在肺中的细胞可以用来调节免疫。 受伤后的反应，但在将这些有希望的发现转化到临床上一直存在挑战。在……里面 与此同时，研究人工肺和无细胞肺使用的生物工程研究激增。 基质作为三维肺或呼吸道再生的支架，最近尝试了一些 在大型动物模型中进行移植。这些研究与那些利用干细胞的研究相结合， 诱导多能干细胞衍生品和/或细胞疗法是一个很有前途且发展迅速的研究。 区域。与这些研究进一步平行的是，对分子和分子的理解显著增加 内源性肺干细胞和/或祖细胞在肺内产生和分化的细胞事件 在肺损伤后的正常和病理修复和重塑中。我们已经举办了八次 2005年至2019年在佛蒙特大学举行的前两年期会议。这些都带来了 将领先的国际调查人员与初级教职员工和实习生一起迅速讨论 移动的场地。这些会议非常成功，并产生了一系列指导方针 研究人员和资助机构都要利用的基础、转译和临床研究。作为研究 关于干细胞和细胞疗法治疗肺部疾病的研究继续快速发展，该领域探索如何 为了最好地翻译这些方法，我们建议再次召集相关调查人员以及 来自NHLBI、FDA和主要非营利性呼吸道疾病基金会的代表讨论当前 问题。特别要讨论的一个领域是基础研究和翻译研究之间的平衡，以及 临床试验的作用，特别是现在已经有各种细胞类型的临床研究 一些情况，包括ARDS、BPD、COPD、IPF、肺动脉高压、败血症，以及最近的情况 新冠肺炎。与以往的会议一样，将特别关注正在崛起的初级调查员和受训人员以及 如何进一步发展这一领域的事业。一如既往，初级调查员、实习生和来自 代表不足的少数群体将优先纳入会议组织、口头陈述、 主持活动、讨论和海报会议。受训者将能够竞争增加的人数 基于对提交的摘要的盲目审查而获得的旅行奖励。会议计划于2021年7月在 佛蒙特大学计划从混合会议切换到完全在线会议，如果 由于正在进行的新冠肺炎大流行限制，有必要这样做。我们预计，本次会议将继续 促进广泛的讨论和辩论，并将在基础、翻译和临床方面显著指导方向 研究干细胞、细胞疗法和肺部疾病的生物工程方法。

Repair and regeneration of diseased lung with stem cells or bioengineered tissue are exciting potential therapeutic approaches for a variety of lung diseases and critical illnesses. Increasing evidence in preclinical models suggests that cells which are not normally resident in the lung can be utilized to modulate immune responses after injury, but there have been challenges in translating these promising findings to the clinic. In parallel, there has been a surge in bioengineering studies investigating use of artificial and acellular lung matrices as scaffolds for three-dimensional lung or airway regeneration, with some recent attempts of transplantation in large animal models. The combination of these studies with those utilizing stem cells, induced pluripotent stem cell derivatives, and/or cell therapies is a promising and rapidly developing research area. These studies have been further paralleled by significant increases in understanding the molecular and cellular events by which endogenous lung stem and/or progenitor cells arise and differentiate during lung development and in normal and pathologic repair and remodeling after lung injury. We have held eight previous biennial conferences at the University of Vermont from 2005 through 2019. These have brought together leading international investigators with junior faculty and trainees to discuss issues in this rapidly moving field. These conferences have been highly successful and have resulted in a series of guidelines for basic, translational, and clinical research to be utilized by both investigators and funding agencies. As studies on stem cell and cell therapies for lung diseases continues to move at a rapid pace and the field explores how to best translate these approaches, we propose to again convene the relevant investigators as well as representatives from the NHLBI, FDA, and leading non-profit respiratory disease foundations to discuss current issues. One area in particular to be discussed is the balance between basic and translational research and the role of clinical trials, particularly as there have now been clinical investigations of various cell types for a number of conditions including ARDS, BPD, COPD, IPF, pulmonary hypertension, sepsis, and more recently COVID-19. As with prior conferences a particular focus will be on rising junior investigators and trainees and how to further develop careers in this area. As always, junior investigators, trainees, and investigators from underrepresented minority groups will be prioritized for inclusion in conference organization, oral presentations, chairing activities, discussions, and poster sessions. Trainees will be able to compete for an increased number of travel awards based on blinded review of submitted abstracts. The conference is planned for July 2021 at the University of Vermont with plans for a switch from a hybrid conference to a fully online conference if necessary due to ongoing COVID-19 pandemic restrictions. We anticipate that this conference will continue to foster extensive discussion and debate and will significantly guide directions in basic, translational, and clinical research of stem cells, cell therapies, and bioengineering approaches for lung diseases.